|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2003-2-4
|
|
pubmed:abstractText |
The risk factors associated with the progression of IgA nephropathy (IgAN), the most common form of glomerulonephritis, are unclear. It has been suggested that CD14 signalling in response to various microbes affects the natural history of chronic inflammatory conditions. It has been hypothesised that variants in the promoter region of the CD14 gene might alter the expression of CD14, and this in turn could influence the progressive nature of IgAN. PCR-RFLP was used to determine the polymorphism at the -159 site (T to C). The distribution of the CD14/-159 polymorphism was no different in patients with IgAN (n=216) compared to 171 healthy controls. After follow up for 86 months, it was found that an excess of the C genotype occurred in patients with progressive disease (p=0.03) and the risk of disease progression increased as the number of C alleles increased (p for trend = 0.002). The hazard ratio for progression in the patients with the CC genotype was 3.2 (p=0.025) compared with the patients possessing the TT genotype. After LPS stimulation, sCD14 was released more abundantly from the PBMCs of the TT subjects than from that of the CC subjects (p=0.006), even though mCD14 expression level was no different. In addition, the TT subjects released less IL-6 than the CC subjects after stimulation (p=0.0003). These results suggest that the CD14/-159 polymorphism is an important marker for the progression of IgAN and may modulate the level of the inflammatory responses.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-10226067,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-10364168,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-10490993,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-10768924,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-10792601,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-10866131,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-10922300,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-10998139,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-11062479,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-11062499,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-11095664,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-11274165,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-11282774,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-11434507,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-11489942,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-12006789,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-12126249,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-2063844,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-3385210,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-7512565,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-7534618,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-7542010,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-7723227,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-8064223,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-9259580,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-9411782,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-9617774,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12566518-9623541
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1468-6244
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
40
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
104-8
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:12566518-Adult,
pubmed-meshheading:12566518-Alleles,
pubmed-meshheading:12566518-Antigens, CD14,
pubmed-meshheading:12566518-Cytidine Triphosphate,
pubmed-meshheading:12566518-Disease Progression,
pubmed-meshheading:12566518-Female,
pubmed-meshheading:12566518-Follow-Up Studies,
pubmed-meshheading:12566518-Glomerulonephritis, IGA,
pubmed-meshheading:12566518-Heterozygote,
pubmed-meshheading:12566518-Homozygote,
pubmed-meshheading:12566518-Humans,
pubmed-meshheading:12566518-Male,
pubmed-meshheading:12566518-Middle Aged,
pubmed-meshheading:12566518-Polymorphism, Genetic,
pubmed-meshheading:12566518-Survival Analysis,
pubmed-meshheading:12566518-Thymine Nucleotides
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Association of the CD14 gene -159C polymorphism with progression of IgA nephropathy.
|
|
pubmed:affiliation |
Seoul National University Hospital Clinical Research Institute, Seoul, Korea.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
